Is lowering low-density lipoprotein an effective strategy to reduce cardiac risk?

“It is not good to settle into a set of opinions. At firstputting forth great effort to be sure that you havegrasped the basics, then practicing so that they maycome to fruition is something that will never stop foryour whole lifetime. Do not rely on following thedegree of understanding that you have discovered,but simply think. . .This is not enough.”Hagakure

[1]  Natural history of myocardial infarction in the coronary drug project: long-term prognostic importance of serum lipid levels. Coronary Drug Project Research Group. , 1978, The American journal of cardiology.

[2]  M. Laakso,et al.  Isolated Low HDL Cholesterol: An Insulin-Resistant State , 1994, Diabetes.

[3]  A. Klimow.  [High-density lipoproteins and arteriosclerosis]. , 1984, Przeglad lekarski.

[4]  Christopher T Sempos,et al.  Non-high-density lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease. , 2006, The American journal of cardiology.

[5]  R H Selzer,et al.  Progression of coronary artery disease predicts clinical coronary events. Long-term follow-up from the Cholesterol Lowering Atherosclerosis Study. , 1996, Circulation.

[6]  N J Wald,et al.  A strategy to reduce cardiovascular disease by more than 80% , 2003, BMJ : British Medical Journal.

[7]  J. Mckenney,et al.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.

[8]  D. Sackett,et al.  The number needed to treat: a clinically useful measure of treatment effect , 1995, BMJ.

[9]  Multiple risk factor intervention trial. Risk factor changes and mortality results. Multiple Risk Factor Intervention Trial Research Group. , 1982, JAMA.

[10]  L. Carlson,et al.  Nicotinic acid: the broad‐spectrum lipid drug. A 50th anniversary review , 2005, Journal of internal medicine.

[11]  Catherine Sudlow,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[12]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[13]  S. Ellis,et al.  Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation. , 1995, Journal of the American College of Cardiology.

[14]  A. Gotto,et al.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.

[15]  J. Critchley,et al.  Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. , 2003, JAMA.

[16]  Paul M Ridker,et al.  Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? , 2004, Circulation.

[17]  A. Hoffer,et al.  Influence of nicotinic acid on serum cholesterol in man. , 1955, Archives of biochemistry and biophysics.

[18]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[19]  Daniel W. Jones,et al.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. , 2003, Hypertension.

[20]  A. von Eckardstein,et al.  High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[21]  S. Grundy,et al.  Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[22]  N J Wald,et al.  By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? , 1994, BMJ.

[23]  D. Berman,et al.  From Vulnerable Plaque to Vulnerable Patient—Part III: Executive Summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force Report , 2006 .

[24]  H. Superko.  The failure of LDL cholesterol reduction and the importance of reverse cholesterol transport. The role of nicotinic acid , 2006 .

[25]  Jonathan C. Cohen,et al.  Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. , 2006, The New England journal of medicine.

[26]  E. Bolson,et al.  Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. , 2001, The New England journal of medicine.

[27]  R. Altschul.  Niacin in vascular disorders and hyperlipemia , 1964 .

[28]  A. Belanger,et al.  The Framingham study. , 1976, British medical journal.

[29]  M. Poggi,et al.  Plasminogen activator inhibitor-1, adipose tissue and insulin resistance , 2007, Current opinion in lipidology.

[30]  Neil J Stone,et al.  Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines , 2004, Circulation.

[31]  Paul Schoenhagen,et al.  Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. , 2004, JAMA.

[32]  R. Collins,et al.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.

[33]  J. Larosa,et al.  Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. , 1999, JAMA.

[34]  B. Brewer,et al.  Regulation of plasma high-density lipoprotein levels by the ABCA1 transporter and the emerging role of high-density lipoprotein in the treatment of cardiovascular disease. , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[35]  G. Nelson.  Blood Constituents. (Book Reviews: Blood Lipids and Lipoproteins. Quantitation, Composition, and Metabolism) , 1972 .

[36]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .

[37]  S. Grundy,et al.  Hypoalphalipoproteinemia (low high density lipoprotein) as a risk factor for coronary heart disease , 1996, Current opinion in lipidology.

[38]  A. Mattioli,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[39]  R. Collins,et al.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.

[40]  J. Abramson,et al.  Are lipid-lowering guidelines evidence-based? , 2007, The Lancet.

[41]  Philip J. Barter,et al.  Intensive lipid lowering with atorvastatin in patients with stable coronary disease. , 2005, The New England journal of medicine.

[42]  E. Mannarino,et al.  High-density lipoprotein cholesterol and left ventricular hypertrophy in essential hypertension , 2001, Journal of hypertension.

[43]  R. Krauss,et al.  Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP). , 1994, Circulation.

[44]  M. Pfeffer,et al.  AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. , 2006, Journal of the American College of Cardiology.

[45]  HOMAS,et al.  The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels , 2000 .

[46]  Thomas Weber,et al.  Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.

[47]  E. Gong,et al.  Characterization of human high-density lipoproteins by gradient gel electrophoresis. , 1981, Biochimica et biophysica acta.

[48]  J. Kostis,et al.  Effect of niacin supplementation on fibrinogen levels in patients with peripheral vascular disease. , 1998, The American journal of cardiology.

[49]  J J Albers,et al.  Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. , 1990, The New England journal of medicine.

[50]  S. Azen,et al.  Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up. , 1990, JAMA.

[51]  Fernando Costa,et al.  Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. , 2006, Current opinion in cardiology.

[52]  Fernando Costa,et al.  Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. , 2005, Circulation.

[53]  John H Fuller,et al.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial , 2004, The Lancet.

[54]  H. Superko,et al.  Beyond LDL cholesterol reduction. , 1996, Circulation.

[55]  D. Illingworth,et al.  Hypolipidemic effects of HMG-CoA reductase inhibitors in patients with hypercholesterolemia. , 1987, The American journal of cardiology.

[56]  N. Unwin,et al.  Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National , 2009 .

[57]  Christopher P Cannon,et al.  Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. , 2006, Journal of the American College of Cardiology.

[58]  M. McGovern,et al.  Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]). , 2003, The American journal of cardiology.

[59]  Intensive lipid lowering with atorvastatin in patients with stable coronary disease. , 2005, The New England journal of medicine.

[60]  J. Mehta,et al.  Management of dyslipidemia in the primary prevention of coronary heart disease , 2002, Current opinion in cardiology.

[61]  Claude Lenfant,et al.  ACC/AHA/NHLBI clinical advisory on the use and safety of statins. , 2002, Journal of the American College of Cardiology.

[62]  Scandinavian Simvastatin Survival Study Group.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.

[63]  D. Waters,et al.  Effects of cholesterol lowering on the progression of coronary atherosclerosis in women. A Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) substudy. , 1995, Circulation.

[64]  S. Grundy,et al.  Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. , 2002, Archives of internal medicine.

[65]  E. Boerwinkle,et al.  Plasma lipid, lipoprotein cholesterol, and apoprotein distributions in selected US communities. The Atherosclerosis Risk in Communities (ARIC) Study. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

[66]  S. Rössner,et al.  Coronary Drug Project Research Group. , 1978, Atherosclerosis.

[67]  Richard M. Moe,et al.  Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. , 2004, Journal of the American College of Cardiology.

[68]  A. Gotto,et al.  Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). , 1997, The American journal of cardiology.

[69]  P. Wolf,et al.  Heart disease and stroke statistics--2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2006, Circulation.

[70]  Ralph B D'Agostino,et al.  Prediction of Lifetime Risk for Cardiovascular Disease by Risk Factor Burden at 50 Years of Age , 2006, Circulation.

[71]  J. Mckenney,et al.  National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) , 2002 .

[72]  Jeremy N. Morris,et al.  W.H.O. COOPERATIVE TRIAL ON PRIMARY PREVENTION OF ISCHÆMIC HEART DISEASE USING CLOFIBRATE TO LOWER SERUM CHOLESTEROL: MORTALITY FOLLOW-UP Report of the Committee of Principal Investigators , 1980, The Lancet.

[73]  G. Miller,et al.  Separation and quantitation of subclasses of human plasma high density lipoproteins by a simple precipitation procedure. , 1982, Journal of lipid research.

[74]  Bruce R. Brodie,et al.  Effect of Intensive Compared With Moderate Lipid-Lowering Therapy on Progression of Coronary Atherosclerosis A Randomized Controlled Trial , 2004 .

[75]  R. Campbell,et al.  Coronary heart disease in high-risk populations: lessons from Finland. , 1990, European heart journal.

[76]  D. Mozaffarian,et al.  Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2009, Circulation.

[77]  J. Slattery,et al.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.

[78]  Roger A. Renfrew,et al.  Lipid Research Clinics Program. , 1984, JAMA.

[79]  J. Goldstein,et al.  Lowering LDL--Not Only How Low, But How Long? , 2006, Science.

[80]  F. Karpe,et al.  The nicotinic acid receptor–a new mechanism for an old drug , 2004, The Lancet.

[81]  M-heart investigators.  Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS) , 1994, The Lancet.

[82]  Raimund Erbel,et al.  Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. , 2006, JAMA.

[83]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[84]  R. Krauss,et al.  Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty‐person/ten‐country panel , 2006, Journal of internal medicine.

[85]  G J Boerma,et al.  Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). , 1995, Circulation.

[86]  O. Faergeman,et al.  High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. , 2005, JAMA.

[87]  B. G. Brown,et al.  Very intensive lipid therapy with lovastatin, niacin, and colestipol for prevention of death and myocardial infarction A 10-year Familial Atherosclerosis Treatment Study follow-up , 1998 .

[88]  R. Nesto.  Correlation between cardiovascular disease and diabetes mellitus: current concepts. , 2004, The American journal of medicine.

[89]  G. Schonfeld.  Blood lipids and lipoproteins; quantitation, composition and metabolism , 1973 .

[90]  O. Franco,et al.  Cost effectiveness of statins in coronary heart disease , 2005, Journal of Epidemiology and Community Health.

[91]  Stanley Azen,et al.  Coronary Angiographic Changes with Lovastatin Therapy: The Monitored Atherosclerosis Regression Study (MARS) , 1993, Annals of Internal Medicine.

[92]  M J Malloy,et al.  Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. , 1990, JAMA.

[93]  Daniel Steinberg,et al.  Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. , 1988, Archives of internal medicine.

[94]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. , 1995, The New England journal of medicine.